MultiCell Technologies Inc (MCET)

[mc67]

Multicell Technologies Inc. (OTCBB: MCET), was heavily traded today gaining 64.44% in its share price up 0.006 to 0.015. The company put out a press release announcing that they have been granted a European patent for the treatment of cancer covering certain therapeutic candidates. MultiCell Technologies states that increasing evidence suggests that the immune system regulates the development of cancer through several mechanisms. The company has created a new class of recombinant antibody therapeutics which redirect the immune response to specific cancer targets. The recombinant antibody therapeutics help create a potent immune response and stimulate the generation of cytolytic cells and together with MultiCell's therapeutics this has been shown to eradicate cancer and create immune protection against reoccurrence of malignant tumours. Shares of MCET traded the day in the range of 0.012 to 0.018, surging on volume.